Immunwork
Taipei
About Immunwork
Immunwork develops innovative drugs that combine targeting and effector functions to enhance efficacy and safety. The company focuses on creating ultralong-acting analogues, such as TE-8214, an octreotide derivative, and TE-8035, a modified human insulin. Immunwork's drug pipeline addresses immune system diseases and leverages a proprietary technology platform. The company is involved in clinical trials to validate its therapeutic solutions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $23.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2022)
- Website: immunwork.com
- Phone: 886-2-2651-2268
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/immunwork-67217 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.